Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure

Journal of Bone and Mineral Research

Volumn 25, Issue 3, 2010, Pages 440-446

  Body, Jean Jacques ^a   Lipton, Allan ^b   Gralow, Julie ^c   Steger, Guenther G ^d   Gao, Guozhi ^e   Yeh, Howard ^e   Fizazi, Karim ^f  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e AMGEN INC   (United States)

^f INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Bisphosphonates; Bone turnover markers; Clinical trials; Novel entities; Osteoclasts

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; IBANDRONIC ACID; PAMIDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE CANCER; BONE METASTASIS; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE MARKER; DRUG EFFECT; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ELECTROLYTE BLOOD LEVEL; FATIGUE; FEMALE; FEVER; HORMONAL THERAPY; HUMAN; INCIDENCE; LEG PAIN; MALE; MULTIPLE MYELOMA; NAUSEA; OSTEOCLAST; OSTEOLYSIS; PARESTHESIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOLID TUMOR; SPINAL CORD; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; BLOOD; BONE; BONE NEOPLASMS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; PATHOPHYSIOLOGY; SECONDARY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NEOPLASMS; RANK LIGAND;

EID: 77953438942     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.090810     Document Type: Article

References (23)

1. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80: 1588-1594.
2. Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 1998;77:336-340. (Pubitemid 28029553)
3. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008;19:420-432.
4. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-2621. (Pubitemid 38715767)
5. Rosen LS, Gordon DH, Dugan W Jr, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:36-43. (Pubitemid 37553537)
6. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-882. (Pubitemid 38807610)
7. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998;188:997-1001. (Pubitemid 28433427)
8. Lacey DL, Tan HL, Lu J, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000;157:435-448. (Pubitemid 30626907)
9. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93: 165-176. (Pubitemid 28180851)
10. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19:1059-1066.
11. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-1228. (Pubitemid 43342512)
12. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875-4882.
13. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69.
14. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925-4935. (Pubitemid 46223998)
15. Costa L, Demers LM, Gouveia-Oliveira A, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002;20:850-856. (Pubitemid 34111395)
16. Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25:4431-4437. (Pubitemid 350013849)
17. Fizazi K, Lipton A, Mariette X, et al. A randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasm after intravenous bisphosphonates. J Clin Oncol 2009;27:1564-1571.
18. Lipton A, Steger GG, Figueroa J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008;14: 6690-6696.
19. Morony S, Warmington K, Adamu S, et al. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 2005;146:3235-3243. (Pubitemid 41058092)
20. Tometsko M, Roudier M, Canon J, et al. RANKL inhibition causes a greater suppression of tumor-induced osteoclastogenesis than zoledronate treatment in vivo and RANKL rescues osteoclasts from zoledronate killing in vitro [Abstract M076 and Poster]. Am Soc Bone Miner Res 2006;21:S346.
21. Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM. Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol 2008;180:1154-1160.
22. Fizazi K, Beuzeboc P, Lumbroso J, et al. A prospective phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2009;27:2429-2435.
23. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001;357:336-341. (Pubitemid 32128538)